Subjective utility ratings of neuroleptics in treating schizophrenia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Synopsis: This study developed a method for measuring subjective costs and benefits of psychiatric treatments. Forty-one patients rated the relative bothersomeness of symptoms of schizophrenia and side effects of neuroleptics. Thirty-four psychiatrists made parallel ratings from the perspective of the average patient (individual utility) and of the patient's family and society (institutional utility). Psychiatrists predicted patients' ratings moderately well, but misjudged the bothersomeness to patients of 24% of side effects and 20% of symptoms. When considering the patient's perspective, both schizophrenic patients and psychiatrists rated symptoms as no more bothersome than side effects. However, psychiatrists saw side effects as significantly less bothersome than symptoms when considering costs to society. The subjective utility of neuroleptic medications for schizophrenia is most justifiable from an institutional perspective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The treatment utility of assessment: A functional approach to evaluating assessment quality.
Hayes, S. C., Nelson, R. O., & Jarrett, R. B. (1987) · American Psychologist · doi:10.1037/0003-066x.42.11.963 · Cited by 486
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Cited by
Antipsychotic-Induced Hyperprolactinaemia: Mechanisms, Clinical Features and Management
Haddad, P. M., & Wieck, A. (2004) · Drugs · doi:10.2165/00003495-200464200-00003 · Cited by 634
Sexual dysfunction in patients taking conventional antipsychotic medication
Smith, S., O'Keane, V., & Murray, R. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.181.1.49 · Cited by 256
Sexual dysfunction in schizophrenia: focus on recent evidence
Baggaley, M. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.924 · Cited by 191
“Sexual dysfunction is considered by many schizophrenia patients to be more troublesome than most other symptoms and adverse drug effects (Finn et al., 1990; Lambert et al., 2004) and is a major cause of poor quality of life (Olfson et al.”
BackgroundSexual dysfunction and antipsychotic treatment
Cutler, A. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00113-0 · Cited by 176
“Given that sexual side effects, such as impotence and delayed/painful ejaculation, have been rated by patients as some of the most ‘bothersome’ side effects of antipsychotics (Finn et al., 1990) and were regarded as being as bothersome as the symptoms of schizophrenia, these effects may have an important impact on pat…”
BackgroundByerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815ac4e5 · Cited by 153
Metadata
- Authors
- Finn, S. E., Bailey, J. M., Schultz, R. T., & Faber, R.
- Venue
- Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 1990-11
- Volume
- 20
- Issue
- 4
- Pages
- 843-848
- ISSN
- 0033-2917 (ISSN-L)
- 1469-8978
- OpenAlex
- W2113297498
- Cited by
- 120
- References
- 2
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subjective utility ratings of neuroleptics in treating schizophrenia. https://app.cochat.ai/papers/10.1017/s0033291700036539
- The paper
- Finn, S. E., Bailey, J. M., Schultz, R. T., & Faber, R. (1990). Subjective utility ratings of neuroleptics in treating schizophrenia. Psychological Medicine. https://doi.org/10.1017/s0033291700036539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.